OPTN (Option Therapeutics) OCF Yield %: 0.00 (As of Jul. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Option Therapeutics OCF Yield %?

Option Therapeutics OPTN OCF Yield % is 0.00 as of Jul. 13, 2026.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Option Therapeutics's Trailing 12-Month Cash Flow from Operations is $-0.71 Mil, and Market Cap is $0.00 Mil. Therefore, Option Therapeutics's OCF Yield % for today is 0.00%.

The historical rank and industry rank for Option Therapeutics's OCF Yield % or its related term are showing as below:


OPTN's OCF Yield % is not ranked *
in the Biotechnology industry.
Industry Median: -8.315
* Ranked among companies with meaningful OCF Yield % only.

Option Therapeutics's OCF Margin % for the quarter that ended in Dec. 2025 was %.

Option Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Option Therapeutics OCF Yield % Related Terms

Option Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for Option Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Option Therapeutics OCF Yield % Chart

Option Therapeutics Annual Data
Trend Jun24 Jun25
OCF Yield %
0.00 0.00

Option Therapeutics Quarterly Data
Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
OCF Yield % Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Option Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Option Therapeutics's OCF Yield % for the fiscal year that ended in Jun. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-1.157 / 0
=N/A%

Option Therapeutics's annualized OCF Yield % for the quarter that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-0.28 * 4 / 0
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of 0.00 mean?
Option Therapeutics (OPTN) has a OCF Yield % of 0.00 as of Jul. 13, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Option Therapeutics and its competitors.
Is Option Therapeutics' OCF Yield % too high?
Option Therapeutics' current OCF Yield % is 0.00.
How does Option Therapeutics' OCF Yield % compare to ?
Option Therapeutics' OCF Yield % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Option Therapeutics and its competitors. Option Therapeutics's current OCF Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Option Therapeutics stock overvalued right now?
Option Therapeutics (OPTN) has a current OCF Yield % of 0.00. The current OCF Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Option Therapeutics (OPTN), the current OCF Yield % is 0.00 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Option Therapeutics Business Description

Comparable Companies
Address 680 West Nye Lane, Suite 201, Carson, NV, USA, 89703
Option Therapeutics Inc is a clinical-stage company developing inventive drug therapies to treat debilitating and life-threatening liver disease through its investigational drug candidate BIV201 (continuous infusion terlipressin). BIV201 is administered as a patent-pending liquid formulation of terlipressin with patents issued, to date, in the U.S., China, Japan, Chile, and India.